This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 3, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of
New Jersey has granted a motion by AstraZeneca seeking a temporary restraining order (TRO) to prevent Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES
® (budesonide inhalation suspension) 0.25, 0.5 mg products. Actavis' sales of generic Pulmicort RESPULES
® have been enjoined until
April 12, 2013 to permit AstraZeneca an opportunity to seek injunctive relief with the U.S. Court of Appeals for the Federal Circuit.
The District Court ruling followed the
April 1, 2013 launch of Actavis' product after the District Court found that Actavis' 0.25, 0.5 and 1 mg generic version of Pulmicort RESPULES
® did not infringe United States Patent No. 7,524,834 (the '834 Patent) and that United States Patent No. 6,598,603 (the '603 Patent) was invalid.
® is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years. For the 12 months ended
January 31, 2013, total U.S. brand and generic sales of Pulmicort RESPULES
® were approximately
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in
Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.
Actavis is the world's third-largest generics prescription drug manufacturer. Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.